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Despite the millions of Euros invested 
in the fight against cancer, and the progress 
made in cancer therapy, a major obstacle to 
winning the war against cancer is the ability 
of cancer cells to metastasize. The process 
of metastasis has been extensively studied, 
and many of the key proteins and pathways 
that facilitate the escape of rogue cells from 
the confines of the primary tumour, their 
use of the vascular system for transporta-
tion, and their eventual colonization of sec-
ondary sites, are well known. However, the 
ability to predict the occurrence of these 
events will occur, with an end goal of better 
targeted therapies, remains the elusive pot 
of gold at the end of the rainbow.  
Cancer of the endometrium, the inner 
membrane of the uterus, is usually curable 
if detected early (Steiner et al., 2003, 2007). 
Unfortunately, recurrence and/or metastasis 
are associated with worse prognosis and 
decreased survival time for the patient. This 
makes endometrial cancer a perfect exam-
ple where the ability to predict metastasis 
will help scientists develop more targeted 
treatments, and increased survival on the 
part of the patient. One approach that has 
some success in predicting metastasis is the 
detection of biomarkers – proteins, genes, 
or small molecules that when present at 
specific levels are indicators of a particular 
biological state, including disease.  
The search for markers of metastasis 
and worse prognosis in endometrial cancer, 
has led to the identification and characteri-
zation of a promising marker and therapeu-
tic target called EDI3 (Endometrial carci-
noma differential 3), published this month 
in the prominent journal, The Proceedings 
of the National Academy of Sciences 
(Stewart et al., 2012). The initial work to 
identify EDI3 was performed in Mainz, 
Germany; where a group of gynaecologists 
tried to identify genes differentially ex-
pressed in primary tumours of patients who 
went on to develop metastasis. Actually the 
endometrial cancer - EDI - project was only 
a small side project in a larger program 
aimed at identifying prognostic markers in 
breast and ovarian cancer (Schmidt et al., 
2008, 2012; Kammers et al. 2011; Cadenas 
et al. 2010, 2011; Petry et al., 2010; Tanner 
et al., 2006). High EDI3 levels were shown 
to predict metastasis and decreased survival 
in both endometrial and ovarian cancers. 
However, the function of EDI3 and how it 
contributed to metastasis was unknown. 
The project travelled to Leipzig and then 
Dortmund, Germany, where most of the 
characterization was performed, supported 
by a group of scientists throughout Germa-
ny and London, UK. With the generous 
support of the EU Seventh Framework Pro-
gramme (FP7) - Health projects Cancersys, 
EDI3 was identified as a member of the 
glycerophosphodiesterase enzyme family, 
and more importantly the first of its kind to 
be implicated in cancer. The substrate for 
EDI3, glycerophosphocholine (GPC), was 
identified, together with the two cleavage 
products, choline and glycerol-3-phosphate, 
both precursors to several lipid metabolism 
pathways. The major hurdle that arose with 
this finding was to try and connect the en-
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zymatic activity of EDI3, as a glyceropho-
diesterase, to metastasis.  
Lipid analysis performed by the group 
of Prof. Gerd Schmitz at the University of 
Regensburg and funded by another FP7 
package, LipidomicNET showed dramatic 
changes to the lipid profile of cells when 
EDI3 was altered. Changes were observed 
for lipids like lysophosphatidic acid and 
phosphatidic acid, both well-known lipid 
mediators already shown to activate signal-
ling pathways, including migration, adhe-
sion, and proliferation – all of which are 
deregulated in cancer. Did EDI3 influence 
these phenotypes? Altering EDI3 in various 
cell models showed that EDI3 is indeed as-
sociated with cellular migration, a process 
critical for metastasis, and the activation of 
protein kinase C was shown to be the path-
way of choice. This finding was significant 
in many ways. It supported once more the 
importance of lipid metabolism in cancer, 
in particular the heavily investigated cho-
line metabolic pathway. Several studies 
have reported elevated levels of total cho-
line, phosphocholine, and decreased levels 
of GPC in many types of cancer compared 
to ‘normal’ tissue. Today, the levels of each 
metabolite in addition to the ratio of GPC to 
phosphocholine are investigated as possible 
biomarkers in several cancers. In addition, 
choline kinase, the enzyme which converts 
choline to phosphocholine is targeted in 
clinical trials, as it too is overexpressed in 
different types of cancer. Our study pre-
sents an alternative and perhaps more rele-
vant target that is not only upstream of cho-
line kinase, but also produces a second 
product G3P that is also a precursor to sev-
eral lipids implicated in tumorigenesis. So 
much more is known about that gene, EDI3, 
which was scraped from a silver stained gel 
almost 10 years ago, but with the many an-
swers also came many questions that will 
surely confirm EDI3’s importance in lipid 
metabolism and its potential importance as 
a chemotherapeutic target.  
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